Cu Treatment Planning and Cu Therapy with Radiolabeled [Cu/Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry.

Our aim was to report the use of Cu and Cu as a theranostic pair of radionuclides in human subjects. An additional aim was to measure whole-organ dosimetry of Cu and Cu attached to the somatostatin analog octreotate using the sarcophagine MeCOSar chelator (SARTATE) in subjects with somatostatin receptor-expressing lesions confined to the cranium, thereby permitting normal-organ dosimetry for the remainder of the body. Pretreatment PET imaging studies were performed up to 24 h after injection of [Cu]Cu-SARTATE, and normal-organ dosimetry was estimated using OLINDA/EXM.

Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer.

The majority of patients with late stage castration-resistant prostate cancer (CRPC) develop bone metastases that often result in significant bone pain. Therapeutic palliation strategies can delay or prevent skeletal complications and may prolong survival. An alpha-particle based therapy, radium-223 dichloride (²²³RaCl₂), has been developed that delivers highly localized effects in target areas and likely reduces toxicity to adjacent healthy tissue, particularly bone marrow.

Time-efficient method for the determination of 210Pb, 210Bi, and 210Po activities in seawater using liquid scintillation spectrometry.

A novel method has been developed for determining the natural decay series radionuclides (NDS), 210Pb, 210Bi, and 210Po, in seawater by way of state-of-the-art liquid scintillation spectrometry. For 210Pb analysis, the method makes use of a 212Pb yield tracer, prepared by ion exchange separation from aged Th(NO3)4. 210Bi recovery is determined using 207Bi as the yield tracer, and 210Po is determined using the conventional 208Po yield tracer.